Increased risk of stroke in patients with bullous pemphigoid: A population-based follow-up study

Stroke

Volumn 42, Issue 2, 2011, Pages 319-323

  Yang, Ya Wen ^a   Chen, Yi Hua ^b   Xirasagar, Sudha ^c   Lin, Herng Ching ^b  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

bullous pemphigoid; epidemiology; stroke

Indexed keywords

ARTICLE; BULLOUS PEMPHIGOID; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; POPULATION SURVEILLANCE; RISK FACTORS; STROKE;

EID: 79251620328     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.596361     Document Type: Article

References (46)

1. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, Lorette G, Bonnetblanc JM, Prost C. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995;131:48-52.
2. Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Brocker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 1995;131: 957-958.
3. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell. 1981;24:897-903.
4. Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P, Treudler R, Zouboulis CC, Schuler G, Borradori L, Hertl M. BP230-and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol. 2004;122:1413-1422.
5. Lever WF. Pemphigus and pemphigoid. A review of the advances made since 1964. J Am Acad Dermatol. 1979;1:2-31.
6. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977; 113:1043-1046.
7. Hadi SM, Barnetson RS, Gawkrodger DJ, Saxena U, Bird P, Merrett TG. Clinical, histological and immunological studies in 50 patients with bullous pemphigoid. Dermatologica. 1988;176:6-17.
8. Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333:1475-1484.
9. Bystryn JC, Rudolph JL. Why is the mortality of bullous pemphigoid greater in Europe than in the US? J Invest Dermatol. 2005;124:xx-xxi.
10. Joly P, Benichou J, Lok C, Hellot MF, Saiag P, Tancrede-Bohin E, Sassolas B, Labeille B, Doutre MS, Gorin I, Pauwels C, Chosidow O, Caux F, Estève E, Dutronc Y, Sigal M, Prost C, Maillard H, Guillaume JC, Roujeau JC. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol. 2005;141:691-698.
11. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122: 1091-1095.
12. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134:465-469.
13. D'Auria L, Mussi A, Bonifati C, Mastroianni A, Giacalone B, Ameglio F. Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity. J Eur Acad Dermatol Venereol. 1999;12:11-15.
14. Ameglio F, D'Auria L, Cordiali-Fei P, Mussi A, Valenzano L, D'Agosto G, Ferraro C, Bonifati C, Giacalone B. Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels. J Biol Regul Homeost Agents. 1997;11:148-153.
15. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol. 1995;25(suppl 2):S9-S12.
16. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck J. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke. 2002;33:2156-2163.
17. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol. 1979;101:521-534.
18. Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke. 2001;32:2131-2136.
19. Echigo T, Hasegawa M, Inaoki M, Yamazaki M, Sato S, Takehara K. Antiphospholipid antibodies in patients with autoimmune blistering disease. J Am Acad Dermatol. 2007;57:397-400.
20. Langan SM, Hubbard R, Fleming K, West J. A population-based study of acute medical conditions associated with bullous pemphigoid. Br J Dermatol. 2009;161:1149-1152.
21. Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41:266-268.
22. Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, Ormerod AD. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol. 2005;153: 424-427.
23. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.
24. Parker SR, Dyson S, Brisman S, Pennie M, Swerlick RA, Khan R, Manos S, Korman BD, Xia Z, Korman NJ. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol. 2008;59: 582-588.
25. Cordel N, Chosidow O, Hellot MF, Delaporte E, Lok C, Vaillant L, Bernard P, D'Incan M, Roujeau JC, Joly P; French Study Group of Bullous Diseases. Neurological disorders in patients with bullous pemphigoid. Dermatology. 2007;215:187-191.
26. Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z. Bullous pemphigoid and internal diseases - a case-control study. Eur J Dermatol. 2010;20:96-101.
27. Nakashima H, Fujimoto M, Asashima N, Watanabe R, Kuwano Y, Yazawa N, Maruyama N, Okochi H, Kumanogoh A, Tamaki K. Serum chemokine profile in patients with bullous pemphigoid. Br J Dermatol. 2007;156:454-459.
28. Echigo T, Hasegawa M, Shimada Y, Inaoki M, Takehara K, Sato S. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol Res. 2006;298:38-45.
29. Tamaki K, So K, Furuya T, Furue M. Cytokine profile of patients with bullous pemphigoid. Br J Dermatol. 1994;130:128-129.
30. Sun CC, Wu J, Wong TT, Wang LF, Chuan MT. High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities. Br J Dermatol. 2000;143:1235-1240.
31. Inaoki M, Takehara K. Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid. J Dermatol Sci. 1998;16:152-157.
32. Ameglio F, D'Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol. 1998; 138:611-614.
33. D'Auria L, Pietravalle M, Mastroianni A, Ferraro C, Mussi A, Bonifati C, Giacalone B, Ameglio F. IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res. 1998; 290:25-27.
34. D'Auria L, Cordiali Fei P, Pietravalle M, Ferraro C, Mastroianni A, Bonifati C, Giacalone B, Ameglio F. The serum levels of sE-selectin are increased in patients with bullous pemphigoid or pemphigus vulgaris. Correlation with the number of skin lesions and recovery after corsticosteroid therapy. Br J Dermatol. 1997;137:59-64.
35. Elkind MS. Inflammatory markers and stroke. Curr Cardiol Rep. 2009; 11:12-20.
36. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
37. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
38. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med. 1994;96:3-9.
39. Boddi M, Prisco D, Fedi S, Cellai AP, Liotta AA, Parretti E, Mecacci F, Mello G, Abbate R. Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes. Thromb Res. 1996;82: 207-216. (Pubitemid 26171624)
40. Colaco CB, Scadding GK, Lockhart S. Anti-cardiolipin antibodies in neurological disorders: cross-reaction with anti-single stranded DNA activity. Clin Exp Immunol. 1987;68:313-319.
41. Nabriski D, Ellis M, Ness-Abramof R, Shapiro M, Shenkman L. Autoimmune thyroid disease and antiphospholipid antibodies. Am J Hematol. 2000;64:73-75.
42. Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1998;43:2507-2512.
43. Roubey RA. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996;39:1444-1454.
44. Riboldi P, Gerosa M, Raschi E, Testoni C, Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology. 2003;207:29-36.
45. Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke. 1996;27:415-420.
46. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR. Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol. 2004;11:49-53.